ArticleCritical care (London, England)2026
Dexmedetomidine on supraventricular tachycardia in critical illness: a time-dependent propensity score matching study.
Article in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dexmedetomidine and supraventricular tachycardia: signal, surrogate, or confounding?Critical care (London, England) · 2026Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSupraventricular tachycardia affects many critically ill patients. Dexmedetomidine, a commonly used sedative, has sympatholytic and vagotonic effects that may alter atrioventricular nodal conduction and contribute to SVT. We aim to determine the association between dexmedetomidine exposure and clinically significant supraventricular tachycardia in a heterogeneous cohort of mechanically ventilated, critically ill adults.
methodsThis retrospective cohort study included critically ill patients from 11 hospitals admitted between July 2018 and October 2022, who were intubated within 48 h of admission. The primary exposure was intravenous dexmedetomidine. The primary outcome was occurrence of clinically significant supraventricular tachycardia, defined as heart rate > 100 beats per minute and administration of intravenous antiarrhythmic drugs. Time-dependent propensity score matching was used to account for time-varying exposures and confounders.
results7,276 patients with dexmedetomidine exposure were matched to 7,276 patients without dexmedetomidine exposure. Clinically significant supraventricular tachycardia occurred more frequently at 7 days in the dexmedetomidine group (n = 1,616, 22.2%) compared to matched controls (n = 1,186, 16.3%, absolute risk difference 5.73%, p < 0.05). After accounting for competing risks, dexmedetomidine use remained associated with a higher risk of supraventricular tachycardia (p < 0.05).
conclusionsDexmedetomidine exposure is associated with clinically significant supraventricular tachycardia in critically ill, mechanically ventilated patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.